Turning Point Therapeutics Stock Forecast, Price & News

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TPTX stock has increased by 159.5% and is now trading at $105.19.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Turning Point Therapeutics or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Turning Point Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Turning Point Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Turning Point Therapeutics.

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.42) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.79) by $0.37.
View Turning Point Therapeutics' earnings history.

6 analysts have issued 1 year price targets for Turning Point Therapeutics' shares. Their forecasts range from $116.00 to $133.00. On average, they anticipate Turning Point Therapeutics' share price to reach $127.33 in the next year. This suggests a possible upside of 21.1% from the stock's current price.
View analysts' price targets for Turning Point Therapeutics.

Turning Point Therapeutics saw a decrease in short interest during the month of October. As of October 30th, there was short interest totaling 2,780,000 shares, a decrease of 16.3% from the October 15th total of 3,320,000 shares. Based on an average daily trading volume, of 449,100 shares, the short-interest ratio is currently 6.2 days.
View Turning Point Therapeutics' Short Interest.

Some companies that are related to Turning Point Therapeutics include CureVac (CVAC), Ono Pharmaceutical (OPHLF), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Catalent (CTLT), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Elanco Animal Health (ELAN), Grifols (GRFS), Sarepta Therapeutics (SRPT), MyoKardia (MYOK), Mirati Therapeutics (MRTX), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA) and Ascendis Pharma A/S (ASND).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), The Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO).

(TPTX) raised $167 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Turning Point Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.70%), State Street Corp (2.69%), Lord Abbett & CO. LLC (1.78%), Federated Hermes Inc. (1.33%), Jennison Associates LLC (1.33%) and Wells Fargo & Company MN (1.29%). Company insiders that own Turning Point Therapeutics stock include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Jingrong Jean Cui, Simeon George and Yi Larson.
View institutional ownership trends for Turning Point Therapeutics.

TPTX stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, AXA S.A., Castleark Management LLC, Advisory Research Inc., Morgan Stanley, Candriam Luxembourg S.C.A., Jennison Associates LLC, and Mackay Shields LLC.
View insider buying and selling activity for Turning Point Therapeutics.

TPTX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Massachusetts Financial Services Co. MA, Wells Fargo & Company MN, Peregrine Capital Management LLC, Emerald Mutual Fund Advisers Trust, Charles Schwab Investment Management Inc., and Emerald Advisers LLC. Company insiders that have bought Turning Point Therapeutics stock in the last two years include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Simeon George, and Yi Larson.
View insider buying and selling activity for Turning Point Therapeutics.

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TPTX stock can currently be purchased for approximately $105.19.

Turning Point Therapeutics has a market capitalization of $5.07 billion. The company earns $-72,130,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Turning Point Therapeutics employs 109 workers across the globe.

The official website for Turning Point Therapeutics is www.tptherapeutics.com.

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]